{"id":49070,"date":"2025-11-26T21:40:01","date_gmt":"2025-11-26T13:40:01","guid":{"rendered":"https:\/\/flcube.com\/?p=49070"},"modified":"2025-11-26T21:40:02","modified_gmt":"2025-11-26T13:40:02","slug":"novartis-remibrutinib-wins-nmpa-approval-for-chronic-spontaneous-urticaria","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49070","title":{"rendered":"Novartis&#8217; Remibrutinib Wins NMPA Approval for Chronic Spontaneous Urticaria"},"content":{"rendered":"\n<p><strong>Novartis AG<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVS:NYSE\">NYSE: NVS<\/a>) announced that <strong>remibrutinib tablets<\/strong> received <strong>National Medical Products Administration (NMPA) approval<\/strong> for the treatment of <strong>chronic spontaneous urticaria (CSU)<\/strong> in adults who remain symptomatic despite H1 antihistamine treatment, based on positive results from the <strong>REMIX\u20111 and REMIX\u20112 Phase\u202f3 trials<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Remibrutinib tablets<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Novartis AG (NYSE: NVS)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>New drug approval<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Chronic spontaneous urticaria (CSU)<\/td><\/tr><tr><td><strong>Study Basis<\/strong><\/td><td>REMIX\u20111 and REMIX\u20112 Phase\u202f3 trials<\/td><\/tr><tr><td><strong>Key Features<\/strong><\/td><td>BTK inhibitor; fast onset (1 week); durable effect (52 weeks)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile\">Drug Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> <strong>Bruton&#8217;s tyrosine kinase (BTK) inhibitor<\/strong> that blocks the BTK cascade and inhibits histamine and inflammatory mediator release responsible for itchy wheals and swelling<\/li>\n\n\n\n<li><strong>Clinical Efficacy:<\/strong> REMIX\u20111 and REMIX\u20112 demonstrated <strong>significant improvement as early as Week\u202f1<\/strong>, with durable effects <strong>up to Week\u202f52<\/strong> in patients refractory to second\u2011generation antihistamines<\/li>\n\n\n\n<li><strong>Safety Profile:<\/strong> Maintained <strong>good tolerability and safety<\/strong> during long\u2011term treatment; adverse events consistent with BTK inhibitor class<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> First <strong>BTK inhibitor<\/strong> approved for CSU in China, offering a new targeted mechanism beyond antihistamines<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-outlook\">Market Context &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>China CSU Patients<\/strong><\/td><td>~<strong>1.8\u202fmillion<\/strong> adults (2024)<\/td><\/tr><tr><td><strong>Antihistamine\u2011Refractory Share<\/strong><\/td><td>~40% (720,000 patients)<\/td><\/tr><tr><td><strong>CSU Market Size (China)<\/strong><\/td><td>\u00a53.2\u202fbillion (US$440\u202fmillion)<\/td><\/tr><tr><td><strong>Growth CAGR<\/strong><\/td><td>12% (2024\u20112030)<\/td><\/tr><tr><td><strong>Peak Sales Forecast (Remibrutinib)<\/strong><\/td><td><strong>\u00a52.0\u20112.8\u202fbillion<\/strong> (~US$270\u2011380\u202fmillion) by 2032<\/td><\/tr><tr><td><strong>Market Share Target<\/strong><\/td><td>30\u201135% of refractory CSU patients<\/td><\/tr><tr><td><strong>Competition<\/strong><\/td><td><strong>Roche\u2019s Xolair<\/strong> (omalizumab) dominates biologics; no approved BTK inhibitors; Novartis\u2019s first\u2011mover advantage<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Reimbursement Path:<\/strong> NMPA approval triggers <strong>Priority Review<\/strong> for NRDL inclusion; potential listing <strong>Q4\u202f2026<\/strong><\/li>\n\n\n\n<li><strong>Next Catalysts:<\/strong> Phase\u202fIII data publication <strong>Q1\u202f2026<\/strong>; U.S. sNDA filing <strong>H2\u202f2026<\/strong><\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Strengthens Novartis\u2019s <strong>immunology franchise<\/strong> in China; repurposes BTK platform from oncology to inflammatory diseases<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding remibrutinib\u2019s commercial launch, market penetration, and reimbursement outcomes. Actual results may differ materially due to risks including competitive responses, market adoption rates, and NRDL negotiation outcomes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novartis AG (NYSE: NVS) announced that remibrutinib tablets received National Medical Products Administration (NMPA) approval&#8230;<\/p>\n","protected":false},"author":1,"featured_media":49071,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[140,865,15,33],"class_list":["post-49070","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-novartis","tag-nyse-nvs","tag-product-approvals","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novartis&#039; Remibrutinib Wins NMPA Approval for Chronic Spontaneous Urticaria - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novartis AG (NYSE: NVS) announced that remibrutinib tablets received National Medical Products Administration (NMPA) approval for the treatment of chronic spontaneous urticaria (CSU) in adults who remain symptomatic despite H1 antihistamine treatment, based on positive results from the REMIX\u20111 and REMIX\u20112 Phase\u202f3 trials.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=49070\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novartis&#039; Remibrutinib Wins NMPA Approval for Chronic Spontaneous Urticaria\" \/>\n<meta property=\"og:description\" content=\"Novartis AG (NYSE: NVS) announced that remibrutinib tablets received National Medical Products Administration (NMPA) approval for the treatment of chronic spontaneous urticaria (CSU) in adults who remain symptomatic despite H1 antihistamine treatment, based on positive results from the REMIX\u20111 and REMIX\u20112 Phase\u202f3 trials.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=49070\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-26T13:40:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-26T13:40:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2602.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49070#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49070\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novartis&#8217; Remibrutinib Wins NMPA Approval for Chronic Spontaneous Urticaria\",\"datePublished\":\"2025-11-26T13:40:01+00:00\",\"dateModified\":\"2025-11-26T13:40:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49070\"},\"wordCount\":318,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49070#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2602.webp\",\"keywords\":[\"Novartis\",\"NYSE: NVS\",\"Product approvals\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49070#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49070\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=49070\",\"name\":\"Novartis' Remibrutinib Wins NMPA Approval for Chronic Spontaneous Urticaria - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49070#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49070#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2602.webp\",\"datePublished\":\"2025-11-26T13:40:01+00:00\",\"dateModified\":\"2025-11-26T13:40:02+00:00\",\"description\":\"Novartis AG (NYSE: NVS) announced that remibrutinib tablets received National Medical Products Administration (NMPA) approval for the treatment of chronic spontaneous urticaria (CSU) in adults who remain symptomatic despite H1 antihistamine treatment, based on positive results from the REMIX\u20111 and REMIX\u20112 Phase\u202f3 trials.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49070#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49070\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49070#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2602.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2602.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novartis' Remibrutinib Wins NMPA Approval for Chronic Spontaneous Urticaria\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49070#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novartis&#8217; Remibrutinib Wins NMPA Approval for Chronic Spontaneous Urticaria\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novartis' Remibrutinib Wins NMPA Approval for Chronic Spontaneous Urticaria - Insight, China&#039;s Pharmaceutical Industry","description":"Novartis AG (NYSE: NVS) announced that remibrutinib tablets received National Medical Products Administration (NMPA) approval for the treatment of chronic spontaneous urticaria (CSU) in adults who remain symptomatic despite H1 antihistamine treatment, based on positive results from the REMIX\u20111 and REMIX\u20112 Phase\u202f3 trials.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=49070","og_locale":"en_US","og_type":"article","og_title":"Novartis' Remibrutinib Wins NMPA Approval for Chronic Spontaneous Urticaria","og_description":"Novartis AG (NYSE: NVS) announced that remibrutinib tablets received National Medical Products Administration (NMPA) approval for the treatment of chronic spontaneous urticaria (CSU) in adults who remain symptomatic despite H1 antihistamine treatment, based on positive results from the REMIX\u20111 and REMIX\u20112 Phase\u202f3 trials.","og_url":"https:\/\/flcube.com\/?p=49070","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-26T13:40:01+00:00","article_modified_time":"2025-11-26T13:40:02+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2602.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=49070#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=49070"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novartis&#8217; Remibrutinib Wins NMPA Approval for Chronic Spontaneous Urticaria","datePublished":"2025-11-26T13:40:01+00:00","dateModified":"2025-11-26T13:40:02+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=49070"},"wordCount":318,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=49070#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2602.webp","keywords":["Novartis","NYSE: NVS","Product approvals","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=49070#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=49070","url":"https:\/\/flcube.com\/?p=49070","name":"Novartis' Remibrutinib Wins NMPA Approval for Chronic Spontaneous Urticaria - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=49070#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=49070#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2602.webp","datePublished":"2025-11-26T13:40:01+00:00","dateModified":"2025-11-26T13:40:02+00:00","description":"Novartis AG (NYSE: NVS) announced that remibrutinib tablets received National Medical Products Administration (NMPA) approval for the treatment of chronic spontaneous urticaria (CSU) in adults who remain symptomatic despite H1 antihistamine treatment, based on positive results from the REMIX\u20111 and REMIX\u20112 Phase\u202f3 trials.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=49070#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=49070"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=49070#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2602.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2602.webp","width":1080,"height":608,"caption":"Novartis' Remibrutinib Wins NMPA Approval for Chronic Spontaneous Urticaria"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=49070#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novartis&#8217; Remibrutinib Wins NMPA Approval for Chronic Spontaneous Urticaria"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2602.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49070","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49070"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49070\/revisions"}],"predecessor-version":[{"id":49072,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49070\/revisions\/49072"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/49071"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49070"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49070"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49070"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}